Hoffmann-La Roche: Obesity trials
The registry lists 21 Obesity studies with Hoffmann-La Roche as lead sponsor. 8 are open to participants now and 1 have results posted.
Phase 1 5Phase 2 7Phase 3 8Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular DiseaseNot yet recruitingNCT07918846Phase 3
- A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or ObesityRecruitingNCT07843498Phase 3
- A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 DiabetesRecruitingNCT07843485Phase 3
- A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular DiseaseRecruitingNCT07843472Phase 3
- A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesRecruitingNCT07670416Phase 3
- A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNot yet recruitingNCT07589686Phase 2
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesRecruitingNCT07351058Phase 3
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesRecruitingNCT07351045Phase 3
- A Study of CT-868 in Type 1 Diabetes MellitusCompletedNCT06062069Phase 2Results posted
- A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or OverweightActive, not recruitingNCT07499050Phase 1
- A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or ObesityActive, not recruitingNCT07137585Phase 1
- A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityCompletedNCT07081958Phase 2
- A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsActive, not recruitingNCT06982131Phase 1
- A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityActive, not recruitingNCT06965413Phase 2
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusCompletedNCT06628362Phase 2
- A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityCompletedNCT06525935Phase 2
- Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes MellitusCompletedNCT05814107Phase 1
- A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesCompletedNCT05794581Phase 1
- A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT05110846Phase 2
- Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese AdultsCompletedNCT02706067Phase 4
- A Study of Xenical (Orlistat) in Overweight and Obese AdolescentsCompletedNCT00940628Phase 3